ODI Pharma AB (XSAT:ODI) Other Current Receivables: kr1.10 Mil (As of Mar. 2026)

Author:

Vera Yuan

Director of Data and Quant Analytics at GuruFocus

Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.

View Profile →

Reviewed by:

Charlie Tian

Founder & CEO of GuruFocus

Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

View Profile →

ODI Pharma AB XSAT:ODI

46 GF Score

Price kr2.10

GF Value kr9.62

Valuation Significantly Undervalued

View Full Analysis

Start Your Free 7-Day GuruFocus Premium Trial

Unlock 30-Y financials, GF Score, and 150+ pro screeners →

What is ODI Pharma AB Other Current Receivables?

ODI Pharma AB XSAT:ODI -5.41% 46 Other Current Receivables is kr1.10 Mil as of Mar. 2026. GuruFocus rates XSAT:ODI with a GF Score™ of 46/100 and a GF Value™ of kr9.62 (Significantly Undervalued).

ODI Pharma AB's Other Current Receivables for the quarter that ended in Mar. 2026 was kr1.10 Mil.

ODI Pharma AB's quarterly Other Current Receivables declined from Sep. 2025 (kr1.24 Mil) to Dec. 2025 (kr0.92 Mil) but then increased from Dec. 2025 (kr0.92 Mil) to Mar. 2026 (kr1.10 Mil).

ODI Pharma AB's annual Other Current Receivables increased from Jun. 2023 (kr0.69 Mil) to Jun. 2024 (kr1.50 Mil) and increased from Jun. 2024 (kr1.50 Mil) to Jun. 2025 (kr2.01 Mil).

Try GuruFocus Premium free for 7 days

Unlock GF Score, GF Value, 30-Y financials, and pro screeners.

Get Started →

ODI Pharma AB Other Current Receivables Related Terms

ODI Pharma AB Other Current Receivables Historical Data

* Premium members only.

The historical data trend for ODI Pharma AB's Other Current Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ODI Pharma AB Other Current Receivables Chart

ODI Pharma AB Annual Data

Trend

Jun19

Jun20

Jun21

Jun22

Jun23

Jun24

Jun25

Other Current Receivables

Get a 7-Day Free Trial

0.99

1.04

0.69

1.50

2.01

ODI Pharma AB Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
Other Current Receivables	Get a 7-Day Free Trial															2.04	2.01	1.24	0.92	1.10

46GF Score

ODI Pharma AB XSAT:ODI

Other Current Receivables is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Start Your Free 7-Day GuruFocus Premium Trial

Unlock 30-Y financials, GF Score, and 150+ pro screeners →

ODI Pharma AB Other Current Receivables Calculation

GuruFocus uses a standardized financial statement format for all companies. GuruFocus lists Accounts Receivable, Notes Receivable , Loans Receivable and Other Current Receivables under the "Total Receivables" section.

Frequently Asked Questions Learn more about Other Current Receivables →

What does a Other Current Receivables of kr1.10 Mil mean?

ODI Pharma AB (XSAT:ODI) has a Other Current Receivables of kr1.10 Mil as of Mar. 2026. Other Current Receivables is other current receivables of that not otherwise classified. View historical data on ODI Pharma AB and its competitors.

Is ODI Pharma AB's Other Current Receivables too high?

ODI Pharma AB's current Other Current Receivables is kr1.10 Mil. Overall, ODI Pharma AB has a GF Score™ of 46/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.

How does ODI Pharma AB's Other Current Receivables compare to ZTS and UTHR?

ODI Pharma AB's Other Current Receivables of kr1.10 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good Other Current Receivables for a Drug Manufacturers company?

A good Other Current Receivables depends on the Drug Manufacturers industry context. However, Other Current Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high Other Current Receivables mean?

A high Other Current Receivables can signal that a stock is expensive relative to its fundamentals. Other Current Receivables is other current receivables of that not otherwise classified. View historical data on ODI Pharma AB and its competitors. ODI Pharma AB's current Other Current Receivables is kr1.10 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is ODI Pharma AB stock overvalued right now?

Based on GuruFocus' analysis, ODI Pharma AB (XSAT:ODI) is currently considered Significantly Undervalued. The stock's GF Value™ is kr9.62, compared to a current price of kr2.10 — trading 78.2% below its estimated fair value. The current Other Current Receivables is kr1.10 Mil. ODI Pharma AB's overall GF Score™ is 46/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is Other Current Receivables calculated?

Other Current Receivables is calculated from a company's financial statements. For ODI Pharma AB (XSAT:ODI), the current Other Current Receivables is kr1.10 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is ODI Pharma AB (XSAT:ODI) Overvalued in 2026?

Based on GuruFocus' analysis, ODI Pharma AB stock appears to be undervalued. The current stock price of kr2.10 is trading 78.2% below its estimated GF Value™ of kr9.62. GuruFocus considers ODI Pharma AB to be Significantly Undervalued.

Key valuation signals for XSAT:ODI:

Other Current Receivables: kr1.10 Mil
GF Value™: kr9.62 vs. price of kr2.10 (78.2% below fair value)
GF Score™: 46/100

No single metric tells the full story. See the XSAT:ODI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Start Your Free 7-Day GuruFocus Premium Trial

Unlock 30-Y financials, GF Score, and 150+ pro screeners →